Historique
Auteur I. GIRAUDON
Documents disponibles écrits par cet auteur (49)
Ajouter le résultat à votre sélection Affiner la recherche
A. M. DINES ; D. M. WOOD ; C. YATES ; F. HEYERDAHL ; K. E. HOVDA ; I. GIRAUDON ; R. SEDEFOV ; P. I. DARGAN ; Euro-DEN Research Group | 2015
Dans Clinical Toxicology (Vol.53, n°9, November 2015) Article : PériodiqueCONTEXT: Despite the potential for recreational drugs and new psychoactive substances (NPSs) to cause significant morbidity and mortality, there is limited collection of systematic data on acute drug/NPS toxicity in Europe. OBJECTIVE: To report[...]
G. MENA ; I. GIRAUDON ; E. ALVAREZ ; J. M. CORKERY ; J. MATIAS ; K. GRASAASEN ; N. LLORENS ; P. GRIFFITHS ; J. VICENTE | 2013
Dans European Addiction Research (Vol.19, n°2, February 2013) Article : PériodiqueBackground: Cocaine-related health consequences are difficult to observe. Data on drug users in health-emergency settings may be a useful source of information on consequences that are not visible via other information sources. Methods: Thirty[...]
P. Y. BELLO ; I. GIRAUDON ; M. J. PARENT ; G. CAGNI ; J. M. DELILE ; FRIGAUX H. ; S. MERLE ; L. PLANCKE ; VILLECHENOUX J.-M. ; YIM J.-P. | 2005
Dans Bulletin Epidémiologique Hebdomadaire (n°20, 17 mai 2005) Article : PériodiqueLe contenu des produits du cannabis (herbe, résine, huile), dont le principe actif est le delta-neuf-tétra-hydro-cannabinol (THC), est une question débattue en France et en Europe. Les seules données disponibles en France étaient, jusqu'à présen[...]
F. HEYERDAHL ; K. E. HOVDA ; I. GIRAUDON ; C. B. YATES ; A. M. DINES ; R. SEDEFOV ; D. M. WOOD ; P. I. DARGAN | 2014
Dans Clinical Toxicology (Vol.52, n°10, December 2014) Article : PériodiqueBACKGROUND: The number of new (novel) psychoactive substances (NPS) available in the illegal market is increasing; however, current monitoring of the drug situation in Europe focuses mainly on classical drugs of abuse, with limited emphasis on c[...]
I. GIRAUDON ; D. HEDRICH ; A. PIRONA ; A. NOOR ; J. MOUNTENEY | 2018
Dans Swaps (n°88-89, 1er et 2e trimestre 2018) Article : PériodiqueFRANÇAIS : Avec au moins 9 100 overdoses, ou décès provoqués par la drogue, en Europe en 2016 - en augmentation de 4% depuis 2015 - la consommation de drogues illicites représente un véritable défi de santé public (EMCDDA European Drug Report 2[...]
This report provides an update on drug-related deaths in Europe based primarily on presentations and discussions held at the 2019 meeting of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) expert network on drug-related deat[...]
On 30 September and 1 October 2021, the EMCDDA brought together more than 60 European and international experts for the annual meeting on the key indicator Drug-related deaths. The online meeting provided a space for sharing and discussing new d[...]
EMCDDA Conference on 20 years of monitoring and communicating evidence on drugs (21-22 September 2015; Lisbon) ; I. GIRAUDON ; J. MATIAS ; L. MONTANARI ; D. HEDRICH ; R. SIMON ; J. VICENTE | 2015
Document texte diversDrug use, in particular high-risk drug use, is one of the major causes of avoidable mortality among young people in Europe, both directly through overdose and indirectly through drug-related diseases, accidents, violence and suicide. The Drug-r[...]
OEDT = EMCDDA ; I. GIRAUDON ; A. M. DINES ; N. SINGLETON ; A. NOOR ; P. I. DARGAN ; D. WOOD | 2020
RapportENGLISH: This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of th[...]
EMCDDA Conference on 20 years of monitoring and communicating evidence on drugs (21-22 September 2015; Lisbon) ; I. GIRAUDON ; L. WIESSING ; E. KALAMARA ; D. HEDRICH ; R. SIMON ; K. PALCZAK ; J. VICENTE | 2015
Document texte diversDrug-related infectious diseases (DRID) are among the most serious health consequences of drug use. The DRID indicator collects data on the extent of drug-related infections among people who inject drugs. This group is a key population affected [...]
V. A. GYARMATHY ; I. GIRAUDON ; D. HEDRICH ; L. MONTANARI ; B. GUARITA ; L. WIESSING | 2009
Dans Eurosurveillance (Vol.14, n°9, 05 March 2009) Article : PériodiqueProblem drug use in pregnancy affects a sizeable population in Europe. A literature review was carried out of articles in PubMed, European Monitoring Centre for Drugs and Drug Addiction publications, and related documents in order to assess publ[...]
Ecstasy et autres produits de synthèse en France. Etat des lieux issu du dispositif SINTES 1999-2002
FRANÇAIS : Crée en 1999, dans le cadre des orientations du Plan triennal de lutte contre la drogue et de prévention des dépendances, SINTES (Système national de surveillance des toxiques et substances) délivre des informations sur les drogues d[...]
The protocol establishes harmonised criteria to extract process and report cases, based on the information available, at the end point of the chain of certification/ascertainment procedures, at different mortality registries: General Mortality R[...]
This study reveals the substantial levels of morbidity related to cocaine use, translated into the large number of cocaine cases seen in various emergency settings in European countries. This health burden is often not captured by other traditio[...]
O. MIRO ; P. I. DARGAN ; D. M. WOOD ; A. M. DINES ; C. YATES ; F. HEYERDAHL ; K. E. HOVDA ; I. GIRAUDON ; Euro-DEN Plus Research Group ; M. GALICIA | 2019
Dans Clinical Toxicology (Vol.57, n°8, August 2019) Article : PériodiqueObjective: To analyse the epidemiology, clinical picture and emergency department (ED) management of a large series of patients who presented to European EDs after cocaine consumption, comparing data from powder (C-1 group) and crack (C-2 group)[...]
